For patients battling metastatic gastrointestinal stromal tumour (GIST), life often takes a dramatic turn following the diagnosis and commencement of systemic medical treatment. This experience, characterized by a complex interplay of hope and hardship, forms the crux of a study published in the “Clinical Sarcoma Research” journal, providing new insights into the lives of individuals enduring the adverse effects of treatment for metastatic GIST.
This article offers a comprehensive understanding of the findings detailed in the study “Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: a qualitative study” by Lena L. Fauske et al., published in 2019. Through a qualitative, phenomenological, and hermeneutic design that employed in-depth, semi-structured interviews with twenty metastatic GIST patients, the research uncovers the altered reality of patients adapting to ‘a new normal’ brought on by their medical circumstances and treatment regimen.
The Juxtaposition of Chronic Cancer and Perceived Health
A startling revelation from the patient narratives emerged – more than half of the study’s participants experienced severe side effects from their treatment, affecting the quality of their lives. Yet, paradoxically, despite the challenges and the ongoing battle with a chronic cancer, half of these patients still considered themselves healthy, almost dissociating from the term ‘cancer patient’. This dichotomy illustrates a profound gap between the biomedical perspective predominant among healthcare professionals and the subjective lived experiences of metastatic GIST patients.
The ‘Ambivalent Friend’: Life-Prolonging Tyrosine Kinase Inhibitor Treatment
The life-prolonging treatment, mainly comprising tyrosine kinase inhibitor therapy, proves to be a double-edged sword. Patients are locked in an ambivalent relationship with the medication – viewing it as a ‘friend’ that sustains their lives, yet simultaneously struggling with the partially debilitating side effects it induces. This contradiction is a powerful reminder of the intricate emotional and psychological landscape that metastatic GIST patients navigate daily.
Closing the Gap: Healthcare Provider Awareness
The study uncovered an urgent need for a more holistic approach to health from oncology healthcare providers. The pressing goal should be to not only extend the lives of metastatic GIST patients but also to secure an individualized follow-up. Improving communication channels, offering guidance on coping strategies, and adapting treatment plans to accommodate patients’ unique experiences stand as pivotal steps toward empowering patients in their journeys.
The Further Reach of This Research
By exploring the patient perspective, Fauske et al.’s study offers a crucial contribution to contemporary medical literature. It is pivotal in shaping future protocols and guidelines aiming to enhance not just the survival but also the well-being of metastatic GIST patients. The unique DOI of this study is 10.1186/s13569-019-0116-3, and the trial registration is outlined by Lena L. Fauske and her colleagues.
Keywords
1. Metastatic GIST Side Effects
2. Gastrointestinal Stromal Tumor Treatment
3. Qualitative Cancer Research
4. Tyrosine Kinase Inhibitor Therapy
5. Chronic Cancer Experience
References
1. Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., et al. (1998). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 279(5350), 577–580. doi: 10.1126/science.279.5350.577.
2. Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D., et al. (2001). Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med, 344(14), 1052–1056. doi: 10.1056/NEJM200104053441404.
3. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., et al. (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 347(7), 472–480. doi: 10.1056/NEJMoa020461.
4. DeMatteo R.P., Lewis J.J., Leung D., Mudan S.S., Woodruff J.M., Brennan M.F. (2000). Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg, 231(1), 51–58. doi: 10.1097/00000658-200001000-00008.
5. Hompland I., Bruland O.S., Holmebakk T., Poulsen J.P., Stoldt S., Hall K.S., et al. (2017). Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort. Acta Oncol, 56(10), 1317–1323. doi: 10.1080/0284186X.2017.1330555.
Through this extensive review of the qualitative study’s findings, we hope to raise awareness about the intricacies of treatment side effects on metastatic GIST patient experiences. The insights garnered underscore the imperative to develop treatment plans that are empathetic to the physical, emotional, and psychological ramifications of metastatic cancer. The healthcare community’s responsibility is to discern and bridge the gap between clinical objectivity and patient subjectivity, paving the way for more patient-centric cancer care.